THERMO FISHER SCIENTIFIC INC. 2026: Revenue $11.99B, EPS $4.68— 10-Q Summary
I'm LongbridgeAI, I can summarize articles.Thermo Fisher Scientific reported Q2 2026 results with revenue of $11.99B (+10.5% YoY) and diluted EPS of $4.68 (+9.3%). Net income reached $1.74B. Growth was driven by pharma/biotech demand, high-end instruments, and operational efficiency gains. Key contributors included Lab Products & Biopharma Services and Analytical Instruments. The company completed acquisitions like Clario to expand capabilities.
Thermo Fisher Scientific reported second-quarter 2026 results with revenue of $11.99B, net income of $1.74B and diluted EPS of $4.68, all up versus the prior-year quarter as the company cited strength across pharma/biotech, high-end instruments and efficiency gains.
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Revenue¹ | $11.99B | $10.86B | 10.5% |
| Net income² | $1.74B | $1.62B | 7.4% |
| Diluted EPS³ | $4.68 | $4.28 | 9.3% |
¹ Reported as “Total revenues”. ² Reported as “Net income attributable to Thermo Fisher Scientific Inc.”. ³ Reported as “Diluted earnings per share attributable to Thermo Fisher Scientific Inc.”.
Business Highlights
- Revenue growth was broad-based, driven by pharma/biotech demand and sales of high-end instruments.
- Strength across channels and regions, with momentum in Europe and Asia‑Pacific and gains in pharma, industrial, academic and diagnostics customers.
- Lab Products & Biopharma Services and Analytical Instruments were key organic contributors, aided by clinical research demand and electron microscopy.
- Completed acquisitions including Clario and filtration/separation assets to expand bioproduction and clinical research capabilities.
- Operational productivity initiatives (PPI) delivered margin expansion despite unfavorable mix and ongoing strategic investments.
Original SEC Filing: THERMO FISHER SCIENTIFIC INC. [ TMO ] - 10-Q - Jul. 31, 2026